Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- No Serious Concerns Observed for 4 Vaccines: MHLW Study Groups
January 17, 2012
- US Industry Opinion Divided on Japan’s Participation in TPP Talks
January 17, 2012
- PAFSC’s First Committee on Drugs to Review Zyprexa for Depression in Bipolar Disorder on January 27
January 16, 2012
- MHLW Proposes New Fee for Medical Management of Treatment-Resistant Schizophrenia
January 16, 2012
- MHLW Director Tawaragi Raises 3 Points, Including Risk Management Planning, as Priority Measures for FY2012
January 13, 2012
- MHLW to Strengthen Support for Ultra-Orphan Drug Development
January 13, 2012
- PFSB Calls for Revision of Package Inserts for 15 Products
January 12, 2012
- MHLW Revises Ministerial Ordinance to Prohibit Dispensing Point Services by Pharmacies
January 12, 2012
- MHLW Issues Administrative Notification on Reexamination Period for 8 Products Approved After Partial Changes
January 11, 2012
- MHLW Issues Notification on Change in Clinical Trial Protocols
January 11, 2012
- Nicotine Patch Products Should Remain Class 1 OTC Drugs: PAFSC Subcommittee
January 11, 2012
- JPO Amends Patent Examination GL to Allow Patent Extension for New Formulations Containing Existing APIs
January 10, 2012
- EC Approves Revised Product Labeling for Actos: Takeda
January 10, 2012
- Hyperthyroidism Added to Serious ADR Section of Flolan’s Package Insert
December 28, 2011
- MHLW Commission Says Joint Purchasing an Advantage to Integration of National, Rosai Hospitals
December 28, 2011
- Additional NHI Price Cuts Decided: ¥22.5 Billion for Long-Listed Drugs, ¥2.5 Billion for Generics
December 27, 2011
- PFSB Draft Budget Includes ¥2.1 Bil. to Improve Review, Safety Measures
December 27, 2011
- Reevaluation Recommended for Lysozyme, Pronase
December 26, 2011
- Tougher Restrictions on Reimbursement of Vitamins to Cut ¥15 Bil. from Med. Expenditure
December 26, 2011
- Development Request Withdrawn for Mitoxantrone
December 26, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…